August 31

PARIS, August 31, 2011 - - Solid operating performance confirmed by an improvement in Q2 results - Sales: €15.2billion (+4%) - Current operating profit: €752million (+6%) - 2011 sales target revised upward to €32billion Bouygues turned in a solid operating performance in the first half of 2011, endorsing the full-year roadmap for all the Group's business areas.

ZUTPHEN, The Netherlands, DALLAS and NEW BRUNSWICK, New Jersey, August 31, 2011 - Cryo-Save (Euronext: CRYO, "Cryo-Save"), Europe's leading family stem cell bank launches its unique Cryo-Lip service in the U.S.

BIETIGHEIM-BISSINGEN, Germany, August 31, 2011 - Leading carry solutions brand DICOTA is gearing up for IFA, the global trade show for consumer electronics, which takes place in Berlin from September 2-7, 2011.

LONDON, August 31, 2011 - - With Photo Tickets are now on sale for the Peace One Day O2 Arena show [www.theo2.co.uk and www.seetickets.com] that will include artists Yusuf (Cat Stevens), Eliza Doolittle, Youssou NDour, Afroreggae, Flawless and English National Ballet.

SAINT-PREX, Switzerland, August 31, 2011 - - Rapid and sustained testosterone suppression and improved PSA control may delay time to second-line therapy New data, published in the September issue of TheJournal of Urology, showed that long-term use of FIRMAGON (degarelix) a gonadotropin-releasing hormone therapy (GnRH) approved for the treatment of advanced prostate cancer in both the EU and US, continued to be effective and well tolerated beyond three years.[1] The new study (CS21A) extends the conclusions of the pivotal Phase III study (CS21) in which the risk of prostate-specific antigen (PSA) failure or death was significantly lower in patients on FIRMAGON compared to leuprolide (an LHRH agonist) up to one year.[1] The extension study has now shown that for patients who remained on FIRMAGON, PSA suppression and the effects on PSA progression free survival (PFS) remained consistent over the long term (42 months).[1] In addition, the study looked at patients who crossed over from leuprolide to FIRMAGONafter one year.